Rising prescription drug prices have emerged as a pressing concern in Australia, echoing challenges numerous healthcare systems face worldwide. As those prices rise, not only do they pressure the pockets of customers, but they also put immense stress on the national healthcare finances and the broader economy. From an economic viewpoint, the spiraling costs of medicinal drugs can doubtlessly destabilize the equilibrium between demand and supply, leading to market inefficiencies. Additionally, as drug treatments become less available, it can result in substantial terrible externalities, with residents no longer getting the desired treatments, escalating public fitness issues. Addressing this trouble will become vital, not just for the sake of personal health effects but also for the broader fitness of the Australian financial system.
Background
Like many evolved countries, Australia’s pharmaceutical market has a storied past that dates to the early 20th century. Initially dominated by local manufacturers, the market, step by step, unfolded to international pharmaceutical giants in the mid-1900s. The advent of the Pharmaceutical Benefits Scheme (PBS) in 1948 was a landmark moment for Australia (Weekes, 2020). PBS, a government initiative, aimed to provide sponsored prescription drugs to the population, ensuring that medication remained less costly and accessible. This scheme laid the muse for a healthcare system wherein the authorities were pivotal in negotiating drug charges and maintaining a listing of sponsored medicinal drugs.
Fast ahead to the current, and the state of affairs has shifted appreciably. Despite the ongoing life and growth of the PBS, drug fees in Australia have been on an upward trajectory during the last few decades. Factors such as rising R&D costs, monopolistic behaviors driven by patent protections, and increased demand due to an aging population have contributed to this trend (Liotta, 2021). While the PBS has been instrumental in providing some level of price control, challenges persist, especially with newer, specialized medications with hefty price tags.
A nuanced picture emerges when we juxtapose Australia’s drug prices with those of other countries. For instance, Australia’s drug prices seem relatively lower compared to the United States, primarily due to robust government interventions like the PBS. However, compared to some European nations or Canada, Australia’s prices might appear higher for certain medications (Liotta, 2021). This discrepancy arises from various factors, including differences in price negotiation strategies, patent laws, and healthcare system structures. While Australia has made commendable efforts to keep drug prices in check, the continuous rise in costs underscores the need for further introspection and strategic action.
Economic Concepts
Demand and Supply Analysis
Factors Driving the Demand for Prescription Drugs: Several factors influence the demand for prescription drugs in Australia. First and foremost is the demographic structure; with an aging population, the need for medications to treat age-related ailments has surged (National Academies of Sciences et al., 2017). Additionally, advancements in medical diagnostics mean that diseases are diagnosed more frequently and earlier, leading to increased drug prescriptions. Changes in lifestyle and the prevalence of conditions such as obesity, diabetes, and heart disease also contribute to heightened demand.
Factors Affecting the Supply of Prescription Drugs: On the supply side, the primary drivers include research and development (R&D) initiatives, patent laws, and regulatory approvals. The long and expensive R&D processes and the quest for innovative drugs can sometimes limit the supply (Liotta, 2021), especially if the outcomes are unexpected. While ensuring exclusive selling rights and recuperation of R&D costs, patent protections can also limit generic drug production, affecting the overall supply.
Equilibrium Price Determination: In a traditional market, the intersection of demand and supply curves determines the equilibrium price. However, in the pharmaceutical sector, this equilibrium can be skewed. High demand and limited supply, especially for patented drugs, can increase prices (Morgan et al., 2020). Conversely, when generic alternatives enter the market, supply increases, potentially lowering prices (National Academies of Sciences et al., 2017). However, external interventions, like government price controls and subsidies, can further affect this equilibrium.
Price Elasticity of Demand
Responsiveness of Quantity Demanded to Price Changes: Price elasticity measures how much the quantity demanded responds to a price change. The demand is often inelastic for many prescription drugs, especially those crucial for survival or well-being (Yeung et al., 2018); even if prices rise, patients still need these drugs, and demand stays the same.
Implications of Inelastic Demand: For life-saving drugs with inelastic demand, pharmaceutical companies can set higher prices, knowing that consumers will still buy the medication (Balderrama et al., 2020); this can lead to what some term’ price gouging’, especially when there are no close substitutes for the drug in question.
Market Failures and Externalities
Information Asymmetry between Pharmaceutical Companies and Consumers: One of the significant market failures in the pharmaceutical sector is information asymmetry. Pharmaceutical companies have in-depth knowledge of the drugs’ cost structures, benefits, and side effects, while consumers (Henderson, 2022), even with the best available information, need more knowledge. This imbalance can result in sub-optimal purchasing decisions and might allow firms to set higher prices than if consumers had complete information.
The Role of Government Intervention and Subsidies: Government intervention becomes crucial to correct such market failures and the negative externalities that may arise from unaffordable drug prices (like poor public health outcomes). The PBS in Australia is a prime example where the government negotiates drug prices, ensuring affordability while maintaining a list of subsidized drugs (Henderson, 2022). Such interventions can help bridge the information gap, regulate prices, and meet broader public health objectives.
Interdisciplinary Perspectives
Health and Medicine
The Importance of Affordable Medications for Public Health Outcomes: Access to affordable medications is a cornerstone of an effective healthcare system. When available at reasonable prices, medications can lead to improved health outcomes, reduce hospitalization rates, and enhance the overall quality of life (Essien et al., 2021). A system where essential drugs are priced out of reach for a significant portion of the population risks widening health disparities and leading to a cascade of health issues that could have been preventable or manageable.
The Role of Research and Development in Drug Pricing: From a medical perspective, continuous R&D is paramount to address emerging health challenges and improve existing treatments. However, R&D is resource-intensive, both in terms of time and finances. The costs involved often justify the high prices of innovative drugs, at least from the pharmaceutical companies’ viewpoint. However, this raises questions about how long patients should bear these costs, especially when the same drugs are often cheaper in other countries.
Ethics and Social Justice
Addressing Concerns Related to Price Gouging and Moral Responsibilities: The ethical dimension of drug pricing is profound. Pharmaceutical companies have the right to profit from their innovations and have a moral responsibility towards patients (Morgan et al., 2020). Price gouging, especially for essential or life-saving drugs, presents a significant ethical dilemma. The question becomes: At what point does rightful profit cross into exploitation?
Balancing Profit Motives with Social Responsibilities: While capitalism encourages profit-making, companies, especially those dealing with essential commodities like medications, must balance profit motives with broader social responsibilities (Morgan et al., 2020). Ensuring access to affordable medications can be viewed as a social obligation, given the impact of such access on public health and societal well-being.
Political Science
Government Regulations, International Treaties, and Their Impact on Drug Prices: Political decisions and frameworks significantly shape drug prices. Government regulations, such as patent laws, can either increase drug prices (by granting exclusive selling rights) or decrease them (by allowing generic production after patent expiration) (Jommi et al., 2020). Furthermore, international treaties, like trade agreements, can impact how drugs are priced, mainly if they include provisions related to intellectual property rights or pharmaceutical trade.
Lobbying Efforts of Pharmaceutical Industries: Given its financial prowess, the pharmaceutical industry often engages in lobbying efforts to influence policies in its favor. Such efforts can affect drug approval processes, patent laws, and pricing negotiations. While lobbying is a legal and often essential part of the democratic process, excessive influence can risk corporate interests overshadowing public interests.
Inclusive Perspectives: Stakeholder Analysis
Patients and Consumers
How Rising Prices Affect Consumers: The ramifications of escalating drug prices are immediate and palpable for patients and consumers. Those with chronic diseases requiring lifelong or long-term medication are hit hardest (Jommi et al., 2020). They face choosing between essential medications and other fundamental needs like food, housing, or education.
Economic Burdens and Challenges in Accessing Medication: The rising costs strain individual and family budgets and lead to medication non-adherence. Due to financial constraints, Patients might skip, reduce, or abandon treatment altogether. Such actions can worsen health outcomes, potentially increasing healthcare costs in the long run.
Pharmaceutical Companies
Rationale Behind Setting High Prices: From the perspective of pharmaceutical companies, pricing is a complex equation. It involves recuperating R&D costs, which are notably high given drug development’s uncertainty and time-consuming nature. Furthermore, only a fraction of investigated drugs make it to the market.
Role of R&D Costs, Marketing, and Profit Margins: Apart from R&D, marketing and promotion costs can be substantial. Additionally, companies seek to make profits for their shareholders and invest in future research (Jommi et al., 2020). This combination of costs and desired profits contributes to the final pricing of the drugs.
Healthcare Providers
Challenges Faced by Hospitals and Doctors: Rising drug prices put healthcare providers in a tough spot. Hospitals’ budgets can be strained, and they may struggle to stock essential yet expensive medications (Hasan et al., 2019). On the other hand, doctors may need help prescribing the best possible medication for a patient and considering its affordability.
Impact on Treatment Decisions and Patient Care: Treatment decisions can be affected when the cost becomes a significant factor. Doctors might opt for less effective but cheaper alternatives or deal with non-adherence issues when patients cannot afford the prescribed medications.
Government Entities
Fiscal Implications of Subsidizing Drug Costs: For governments, subsidizing drug prices, as seen with Australia’s PBS, means allocating substantial funds that might otherwise be used for other public services. As drug prices rise, the fiscal burden on the government’s budget intensifies, challenging resource allocation decisions.
Strategies for Regulation and Negotiations with Pharmaceutical Companies: Governments can employ various strategies to counteract rising drug prices. These might include stricter price regulation, negotiations with pharmaceutical companies for bulk purchase discounts, promoting generic drug production, or incentivizing local drug manufacturing (Hasan et al., 2019). Governments often walk a tightrope, ensuring affordable medications for citizens while fostering an environment conducive to pharmaceutical innovations and business growth.
Recommendations
Encourage Generic Drug Production and Competition
One of the effective ways to drive down drug prices is to encourage the production and availability of generic drugs (Rajkumar, 2020). These are typically less expensive than their branded counterparts. By fostering an environment that promotes competition among generic manufacturers, prices can be naturally driven down due to market forces.
Review and Potentially Modify Patent Laws
While patents are crucial to ensure that pharmaceutical companies can recuperate their R&D costs, they must balance this with public health interests (Rajkumar, 2020). Reviewing the duration of patents or considering compulsory licensing in cases of essential drugs can be potential strategies to ensure drugs are affordable, yet companies are incentivized to innovate.
Conclusion
Rising prescription drug prices have raised concerns from multiple fronts, affecting patients, straining healthcare providers, challenging pharmaceutical companies, and burdening government budgets. As we have delved into the complexities of this issue, the importance of addressing drug prices for the broader societal well-being becomes even more apparent. However, more than a singular approach is required. An interdisciplinary approach is crucial to address and resolve this challenge. Tapping into economics, health, ethics, and political science provides a holistic understanding and paves the way for comprehensive solutions. As we move forward, the collaboration of all stakeholders, rooted in mutual understanding and driven by a shared vision of public health, will be the linchpin in ensuring essential medications are accessible and affordable for all.
References
Balderrama, F., Schwartz, L. J., & Longo, C. J. (2020). When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing. Health Care Analysis. https://doi.org/10.1007/s10728-020-00394-x
Essien, U. R., Dusetzina, S. B., & Gellad, W. F. (2021). A Policy Prescription for Reducing Health Disparities—Achieving Pharmacoequity. JAMA, 326(18), 1793. https://doi.org/10.1001/jama.2021.17764
Hasan, S. S., Kow, C. S., Dawoud, D., Mohamed, O., Baines, D., & Babar, Z.-U.-D. (2019). Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in Health Regional Issues, pp. 18, 18–23. https://doi.org/10.1016/j.vhri.2018.08.007
Henderson, J. W. (2022). Health Economics and Policy. In Google Books. Cengage Learning. https://books.google.com/books?hl=en&lr=&id=tSxmEAAAQBAJ&oi=fnd&pg=PP1&dq=Healthcare+Economics:+Key+Features+of+Healthcare+Markets&ots=_0zLM1xoIJ&sig=qRH1yWlRuyyRZUmFuvfQJ2Y_h1E
Jommi, C., Armeni, P., Costa, F., Bertolani, A., & Otto, M. (2020). Implementation of Value-based Pricing for Medicines. Clinical Therapeutics, 42(1), 15–24. https://doi.org/10.1016/j.clinthera.2019.11.006
Liotta, M. (2021). newsGP – The pandemic is challenging Australia’s medication supply chains. NewsGP. https://www1.racgp.org.au/newsgp/professional/pandemic-challenging-australia-s-medication-supply
Morgan, S. G., Bathula, H. S., & Moon, S. (2020). Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ, p. 368, l4627. https://doi.org/10.1136/bmj.l4627
National Academies of Sciences, E., Division, H. and M., Services, B. on H. C., Therapies, C. on E. P. A. to A. D., Nass, S. J., Madhavan, G., & Augustine, N. R. (2017). Factors Influencing Affordability. In www.ncbi.nlm.nih.gov. National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK493090/
Rajkumar, S. V. (2020). The high cost of prescription drugs: Causes and solutions. Blood Cancer Journal, 10(6). https://doi.org/10.1038/s41408-020-0338-x
The Pharmacy Guild of Australia. (2022). The cost of medicines hits hard. Www.guild.org.au. https://www.guild.org.au/news-events/news/forefront/v12n03/cost-of-medicines-hits-hard#:~:text=The%20maximum%20price%20of%20Pharmaceutical
Weekes, L. M. (Ed.). (2020). Improving Use of Medicines and Medical Tests in Primary Care. Springer Singapore. https://link.springer.com/content/pdf/10.1007/978-981-15-2333-5.pdf
Yeung, K., Basu, A., Hansen, R. N., & Sullivan, S. D. (2018). Price elasticities of pharmaceuticals in a value-based-formulary setting. Health Economics, 27(11), 1788–1804. https://doi.org/10.1002/hec.3801
write